当前位置：药药网 / 药品研发 / 美国药品上市后承诺数据库
TRUMENBA, Meningococcal Group B Vaccine
申请企业
Wyeth Pharmaceuticals LLC
药品名称
TRUMENBA, Meningococcal Group B Vaccine
承诺描述
A deferred pediatric study (B1971035) under PREA to evaluate the safety and immunogenicity of Trumenba in children 12 months to less than 24 months of age for the prevention of invasive group B meningococcal disease.
承诺状态描述
The final report was submitted to FDA on 15 Mar 2018.
报告接收日期
2020/12/18 0:00:00